部分代表性论文
- Epigenetic Therapy Inhibits Metastases by Disrupting Premetastatic Niches. Nature. 2020;579 (7798):284-290.
- Challenges in anticancer drug R&D in China. Lancet Oncol. 2019;20(2):183-186.
- Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013, 14(12):e535-47.
- Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015; 12(9): 553-60.
- A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018; 9(1): 1012-1027.
- Efficacy, Safety and Biomarkers of Toripalimab in Patients With Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020 May 15;26(10):2337-2345.
- Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res. 2018; 24(21):5261-5271.
- Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. Theranostics. 2019;9(12):3485-3500.
- Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J Hematol Oncol. 2019 Feb14;12(1):16.
- Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. 2018; 11(1):20-31.
- HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018; 88:92-100.
- A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21(5):782-791.
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric cancer. 2015; 18(1): 168-76.
- Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Lett. 2019;457:142-150
- Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. J Immunother. 2020 May;43(4):139-144.
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019 Mar 5;129 (5):2056-2070.
- iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nature Communications, 2019 Mar 22;10 (1):1336.
- Personalized cancer neoantigen vaccines come of age. Theranostics. 2018; 8 (15):4238-4246.
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Frontiers in Immunology, 2018 May 3;9:978.
- Facile Optimization and Evaluation of PEG–PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery Using Copolymer Hybrids and Histoculture Drug Response Assays. Journal of Biomedical Nanotechnology, 2018 Feb 1;14 (2):321-330.
- mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer. Journal of the National Cancer Institute. 2011;103 (20):1152-1156
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12 (8):735-742.
- Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 2019, 7 (5):437-446.
- Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015, 33 (32):3701-3709.
- Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2015, 26 (9):1877-1883.
- ROS1 fusions in Chinese patients with non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2013, 24 (7): 1822-1827.
- Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2017, 12 (6): e65-e68.
-
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2017, 12 (7): 1085-1097.
- EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2016, 11 (10):1718-1728.
- Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2018, 13 (9):1383-1392.
- Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. Journal of hematology & oncology 2019, 12 (1): 75-75.
2020年3月27日 14:32
ꄘ浏览量：0
